Hummingbird Bioscience, Inc

Stream Biomedical, Inc. is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing innovative therapeutics for the treatment of acute neurotrauma and chronic neurodegenerative diseases. With a commitment to addressing high unmet medical needs, the company leverages cutting-edge science to create first-in-class targeted treatment options. Their research emphasizes cerebrovascular repair and the development of novel solutions for conditions such as stroke, traumatic brain injury, and Alzheimer's disease. Stream Biomedical's advancements include promising neuroprotective therapies and a strong pipeline of publications highlighting their contributions to neurotherapeutic science. Generated from the website

Proxima Clinical Research Inc., also known as Proxima CRO, is a leading contract research organization located in Houston, Texas, specializing in the innovation of medical devices, drugs, and diagnostics. The company combines advanced technology and therapeutic expertise with agile management principles to enhance regulatory clearance and improve capital efficiency in biotech and MedTech programs. With a team of clinical, regulatory, and quality experts, Proxima is dedicated to helping clients navigate industry challenges and achieve their milestones effectively. The organization offers a comprehensive range of services, including consulting, clinical trials, and quality management, tailored to meet the specific needs of life science companies across various therapeutic segments. Generated from the website

BiVACOR Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in innovative solutions for heart failure. The company is developing the BiVACOR Total Artificial Heart (TAH), a groundbreaking device designed to replace the function of a failing heart and provide an effective bridge-to-transplant therapy for patients with severe biventricular heart failure. The BiVACOR TAH utilizes advanced electro-mechanical rotary blood pump technology and magnetic levitation (MAGLEV) to deliver high cardiac output with a compact design. By eliminating mechanical wear and optimizing blood flow, the device aims to enhance patient mobility and improve outcomes for those awaiting heart transplantation. Generated from the website